Cargando…
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
The PI3K–AKT–mTOR pathway is frequently activated in cancer. PI3K inhibitors, including the pan-PI3K inhibitor buparlisib (BKM120) and the PI3Kα-selective inhibitor alpelisib (BYL719), currently in clinical development by Novartis Oncology, may therefore be effective as anticancer agents. Early clin...
Autores principales: | Massacesi, Cristian, Di Tomaso, Emmanuelle, Urban, Patrick, Germa, Caroline, Quadt, Cornelia, Trandafir, Lucia, Aimone, Paola, Fretault, Nathalie, Dharan, Bharani, Tavorath, Ranjana, Hirawat, Samit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708174/ https://www.ncbi.nlm.nih.gov/pubmed/26793003 http://dx.doi.org/10.2147/OTT.S89967 |
Ejemplares similares
-
Challenges in the clinical development of PI3K inhibitors
por: Massacesi, Cristian, et al.
Publicado: (2013) -
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
por: O’Brien, Neil A., et al.
Publicado: (2020) -
Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib
por: Germa, C., et al.
Publicado: (2017) -
Development of Essential Oil Delivery Systems by ‘Click Chemistry’ Methods: Possible Ways to Manage Duchenne Muscular Dystrophy
por: Kaspute, Greta, et al.
Publicado: (2023) -
Observation of $\pi^- K^+$ and $\pi^+ K^-$ atoms
por: Adeva, B., et al.
Publicado: (2016)